Orthomolecular Medicine News Service, October 13, 2020
Commentary by Patrick Holford

(OMNS Oct 13, 2020) The world’s first randomized placebo controlled trial designed to test high dose intravenous vitamin C for treatment of COVID-19 has reduced mortality in the most critically ill patients by two thirds. [1] The study, headed by Professor Zhiyong Peng at Wuhan’s Zhongnan University Hospital, started in February and gave every other critically ill COVID-19 patient on ventilators either 12,000 milligrams (mg) of vitamin C twice daily or sterile water in their drip. Neither the patient nor the doctors knew who was getting vitamin C or placebo so the trial was "double blind." This is the ‘gold standard’ of research design.
Overall, 5 out 26 people (19%) died in the vitamin C group while 10 out of 28 (36%) receiving the placebo died. That means that vitamin C almost halved the number of deaths. Those on vitamin C were 60% more likely to survive.

Keep reading: https://orthomolecular.activehosted....0dd76442e.180&